Abstract: Many of renal failure patients on hemodialysis suffer from itching. Treatment options of such cases are diverse and variable responses are recorded. The most frequently used therapy is UVB phototherapy, eliciting favorable response in most of patients. Promising results have also been obtained by treatment with the anticonvulsant gabapentin. This study aimed to assess the effectiveness of combined treatment of Hemodialysis-associated Pruritus (HAP) with NB-UVB and gabapentin therapy versus NB-UVB alone. Forty eight cases of HAP were enrolled in this study. Cases were randomized into two groups; the 1st group was treated with NB-UVB alone on three sessions’ bases /week and included 24 patients and was termed as “the control group”. The second group was treated with combined NB-UVB sessions on the same bases (3 sessions/week) with addition of gabapentin 300 mg -as a single dose after each hemodialysis session for a similar period (6 weeks) and included another 24 cases and was termed as “the study group”. After treatment, patients were followed up for 6 months for recurrence of pruritus. For every case, the assessment of pruritus was done using the 5-D itch scale, before treatment, at the end of treatment and after 6 months post-treatment for recurrence. A patient was considered as a responder to treatment if he showed 50% or more reduction of his baseline 5-D itch scale at the end of treatment period. Return of the score to/or above the baseline levels after 6 months follow up was used to mark recurrence. Twenty two cases of the control group and twenty one cases of the study group completed the study. In the control group, 14 patients were responders to NB-UVB alone (63.64%) while 8 cases (36.36%) were non-responders. In the study group, 16 cases were responders to combined NB-UVB and gabapentin (76.19%) while 5 patients (23.81%) were non-responders. No statistically significant difference was found between the response rates in both groups (p>0.05). After 6 months follow up, 8 responders in the control group (57.14%) and 2 responders in the study group (12.5%) developed recurrence of pruritus and this was statistically significant (p<0.05). Response to gabapentin and NB-UVB was not significantly superior to NB-UVB alone in treatment of HAP. However, this mode of therapy significantly reduces the rate of recurrence of pruritus.